早期三阴性乳腺癌术后局部复发是一个重大挑战。为了控制残留肿瘤的再生，我们开发了一种用于术中植入的自体治疗性混合纤维蛋白胶。使用自体血清蛋白作为稳定剂，我们优化了高载药拉帕替尼-NanoSera (Lap-NS; ∼66% L.C.) 和咪喹莫特-MicroSera (IMQ-MS; ∼92% L.C.)。此外，还开发了在 980 nm 激光照射下光热转换效率约为 67% 的等离子体纳米血清 (PNS)。虽然 Lap-NS 或 PNS 的局部单一疗法降低了肿瘤的再生率，但它们与 IMQ-MS 的组合放大了免疫原性细胞死亡的影响，并导致手术部位免疫细胞的高水平肿瘤浸润。采用基于 Nano-MicroSera 的混合纤维蛋白植入物的局部联合免疫疗法显示出优异的肿瘤抑制和存活率，具有临床转化的重大前景。

Local recurrence post-surgery in early-stage triple-negative breast cancer is a major challenge. To control the regrowth of a residual tumor, we have developed an autologous therapeutic hybrid fibrin glue for intra-operative implantation. Using autologous serum proteins as stabilizers, we have optimized high drug-loaded lapatinib-NanoSera (Lap-NS; ∼66% L.C.) and imiquimod-MicroSera (IMQ-MS; ∼92% L.C). Additionally, plasmonic nanosera (PNS) with an ∼67% photothermal conversion efficiency under 980 nm laser irradiation was also developed. While localized monotherapy with either Lap-NS or PNS reduced the tumor regrowth rate, their combination with IMQ-MS amplified the effect of immunogenic cell death with a high level of tumor infiltration by immune cells at the surgical site. The localized combination immunotherapy with a Nano-MicroSera based hybrid fibrin implant showed superior tumor inhibition and survival with significant promise for clinical translation.